Prevalence of Transmitted Drug Resistance among HIV-1 Patients in the Aegean Region: Results from the Western Part of Turkey

Simple item page
dc.contributor.authorSertoz R.
dc.contributor.authorTekin D.
dc.contributor.authorErensoy S.
dc.contributor.authorBiceroglu S.
dc.contributor.authorKaptan F.
dc.contributor.authorKöse S.
dc.contributor.authorOzkan H.
dc.contributor.authorCetin B.
dc.contributor.authorTürken M.
dc.contributor.authorGokengin D.
dc.date.accessioned2024-07-22T08:03:19Z
dc.date.available2024-07-22T08:03:19Z
dc.date.issued2023
dc.description.abstractObjectives: This study aimed to analyze the antiretroviral drug resistance in antiretroviral treatment-naïve HIV-positive patients in the Aegean Region of Turkey from 2012 to 2019. Methods: The study included 814 plasma samples from treatment-naïve HIV-positive patients. Drug resistance analysis was performed by Sanger sequencing (SS) between 2012-2017 and by next-generation sequencing sequencing (NGS) between 2018-2019. SS was used to analyze resistance mutations in the protease (PR) and reverse transcriptase (RT) gene regions using a ViroSeq HIV-1 Genotyping System. PCR products were analyzed with an ABI3500 GeneticAnalyzer (Ap-plied Biosystems). The sequencing of the HIV genome in the PR, RT, and integrase gene regions was carried out using MiSeq NGS technology. Drug resistance mutations and subtypes were inter-preted using the Stanford University HIV-1 drug resistance database. Results: Transmitted drug resistance (TDR) mutation was detected in 34/814 (4.1 %) samples. Non-nucleoside reverse transcriptase inhibitor (NNRTI), nucleoside reverse transcriptase inhibitor (NRTI), and protease inhibitor (PI) mutations were identified in 1.4 % (n =12), 2.4 % (n =20), and 0.3 % (n = 3) of samples, respectively. The most common subtypes were B (53.1 %), A (10.9%), CRF29_BF (10.6%), and B + CRF02_AG (8,2%). The most common TDR mutations were E138A (3.4%), T215 revertants (1.7%), M41L (1.5%), and K103N (1.1%). Conclusion: Transmitted drug resistance rate in the Aegean Region is compatible with national and regional data. Routine surveillance of resistance mutations may guide the safe and correct selection of initial drug combinations for antiretroviral therapy. The identification of HIV-1 subtypes and re-combinant forms in Turkey may contribute to international molecular epidemiological data. © 2023 Bentham Science Publishers.
dc.identifier.DOI-ID10.2174/1570162X21666230525145529
dc.identifier.issn1570162X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12223
dc.language.isoEnglish
dc.publisherBentham Science Publishers
dc.subjectAnti-HIV Agents
dc.subjectDrug Resistance, Viral
dc.subjectGenotype
dc.subjectHIV Infections
dc.subjectHIV Seropositivity
dc.subjectHIV-1
dc.subjectHumans
dc.subjectMutation
dc.subjectPrevalence
dc.subjectReverse Transcriptase Inhibitors
dc.subjectTurkey
dc.subjectabacavir
dc.subjectantiretrovirus agent
dc.subjectatazanavir
dc.subjectatazanavir plus ritonavir
dc.subjectdarunavir plus ritonavir
dc.subjectdidanosine
dc.subjectefavirenz
dc.subjectemtricitabine
dc.subjectetravirine
dc.subjectHuman immunodeficiency virus core protein p24
dc.subjectHuman immunodeficiency virus proteinase inhibitor
dc.subjectintegrase
dc.subjectlopinavir
dc.subjectnelfinavir
dc.subjectnevirapine
dc.subjectnonnucleoside reverse transcriptase inhibitor
dc.subjectproteinase
dc.subjectrilpivirine
dc.subjectritonavir
dc.subjectRNA directed DNA polymerase
dc.subjectRNA directed DNA polymerase inhibitor
dc.subjectsaquinavir
dc.subjectstavudine
dc.subjecttenofovir
dc.subjecttipranavir
dc.subjectzidovudine
dc.subjectanti human immunodeficiency virus agent
dc.subjectRNA directed DNA polymerase inhibitor
dc.subjectadolescent
dc.subjectadult
dc.subjectaged
dc.subjectantiretroviral therapy
dc.subjectantiviral resistance
dc.subjectArticle
dc.subjectchemiluminescent microparticle immunoassay
dc.subjectchild
dc.subjectdisease transmission
dc.subjectfemale
dc.subjectgene mutation
dc.subjectgenotyping
dc.subjecthigh throughput sequencing
dc.subjecthuman
dc.subjectHuman immunodeficiency virus 1 infection
dc.subjectHuman immunodeficiency virus infected patient
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectreverse transcription polymerase chain reaction
dc.subjectSanger sequencing
dc.subjectTurkey (republic)
dc.subjectvirus genome
dc.subjectantiviral resistance
dc.subjectgenetics
dc.subjectgenotype
dc.subjectHuman immunodeficiency virus 1
dc.subjectHuman immunodeficiency virus infection
dc.subjectmutation
dc.subjectprevalence
dc.subjectturkey (bird)
dc.titlePrevalence of Transmitted Drug Resistance among HIV-1 Patients in the Aegean Region: Results from the Western Part of Turkey
dc.typeArticle

Files

Collections

Scopus Koleksiyonu